

ASLAN appoints Andrew Howden in director's board

29 February 2016 | News | By BioSpectrum Bureau

ASLAN appoints Andrew Howden in director's board



Singapore: ASLAN Pharmaceuticals, Singapore based biotech company focused on the development of immunotherapies and targeted agents for Asia prevalent tumour types, has appointed Andrew Howden as an Independent Non-Executive Director.

Mr Howden is a senior pharmaceutical executive with almost 35 years of experience from the global pharmaceutical industry and has established a strong track record in clinical research, business development and commercialisation. Most recently, he was Chief Executive Officer of iNova Pharmaceuticals in Australia where he led an active business development strategy until its acquisition by Valeant Pharmaceuticals International. Andrew oversaw the integration of iNova Pharmaceuticals and led the expansion of the company's Asia Pacific operations until 2015.

Prior to iNova Pharmaceuticals, Andrew was President of IMS Health's Asia Pacific region, Regional Vice President Asia Pacific at AstraZeneca, and held senior roles at Quintiles in Europe and Asia.

Mr Howden holds a Bachelor of Science degree and a Masters of Commerce from the University of New South Wales, Australia.